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Abstract
As previously indicated an association may exist between early sleep problems in infants and toddlers, and a diagnosis of 
attention deficit hyperactivity disorder (ADHD). The aim of this study was to study if this association could be replicated in 
a complete nationwide cohort of children. Prospective cohort study using national registries. All children born in Norway 
from January 2004 to December 2010 were included (N = 410,555). Information on hypnotic drugs dispensed to children 
0–3 years of age outside of institutions was collected from the Norwegian Prescription Database and used as a proxy for sleep 
problems. The outcome ADHD (ICD-10), as diagnosed by specialists in the Child Mental Health Service, was obtained from 
the Norwegian Patient Registry. Data were analysed using weighted estimation in Cox regression. The unadjusted weighted 
hazard ratio (wHR) for a later diagnosis of ADHD in children dispensed two or more prescriptions for any hypnotic drug, 
compared to zero prescriptions, was 2.30 [95% confidence interval (CI) 1.63–3.23] for girls and 1.75 (95% CI 1.48–2.07) for 
boys. For the sedative antihistamine trimeprazine the corresponding wHR was 3.71 (95% CI 1.83–7.52) for girls and 2.78 
(95% CI 2.04–3.80) for boys. After adjusting for parental ADHD and parental education the wHR for trimeprazine users was 
2.81 (95% CI 1.34–5.88) for girls and 2.33 (95% CI 1.70–3.20) for boys. Infants and toddlers who were dispensed hypnotics 
had an increased risk of ADHD at school age. This association was most pronounced with the use of trimeprazine, a drug 
traditionally prescribed to toddlers for sleep problems in Norway. After adjusting for parental ADHD and educational level 
the risk for ADHD among the trimeprazine users was still more than twice the risk among controls.
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Abbreviations
ADHD  Attention deficit hyperkinetic disorder
NorPD  Norwegian Prescription Database
NPR  Norwegian Patient Registry
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Introduction
Regulation problems such as sleep–wake regulation, crying 
and transition to solid foods are important challenges for all 
human babies in the first years of life [1], and problems in 
these areas often occur together [2, 3]. Longitudinal stud-
ies have shown that early regulatory problems are associ-
ated with later emotional and behavioural problems [2, 3], 
a relationship also found when the regulatory problems are 
early sleep problems [4–7]. Sleep problems also seem to be 
related to the later development of ADHD symptoms [3, 
8–10]. Studies using diagnoses of ADHD as outcome are 
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fewer and results more inconsistent. One study indicated that 
about one in four children with severe sleep problems quali-
fied for a diagnosis of ADHD at an age of 5.5 years [11], 
confirmed by a retrospective study where parents of chil-
dren with a diagnose of ADHD at 8–9 years of age reported 
persistently elevated levels of sleep problems from infancy 
[12]. However, a population based longitudinal study among 
8253 children found shortened sleep at the age of 5, but not 
earlier, to be associated with ADHD at the age of 7 years 
[13]. In a different study sleep problems at the age of 4 years 
did not predict ADHD diagnosis at the age of 6 when early 
symptoms of the disorder were adjusted for [14].
Pharmacological treatment of childhood sleep problems 
is frequent in many countries [15, 16]. An Australian study 
found that among parents of children 0–24 months, 6% had 
received an over-the-counter (OTC) medicine to induce 
sleep in the child [17]. In Norway there is a long standing 
clinical tradition of prescribing the antihistamine trimepra-
zine for infants and toddlers with sleep problems [18, 19], 
even if there have been some concern about the effect and 
safety of the drug in this age group [20–22]. The use of 
trimeprazine has declined over the last 10 years [23, 24]. 
Some 3% of the children born in 2008 filled a prescription 
for the drug before 3 years of age and the peak incidence of 
trimeprazine prescriptions at age 18 months [25].
Norway has several national health registries with com-
pulsory and automatically collected information. Several 
registries can be linked on an individual level, making it pos-
sible to conduct large cohort studies, with information from 
different sources and follow up over time. In such national 
registries, only emigrants are lost to follow up. We wanted 
to utilize these registries to create a large-scale cohort and 
study if previous findings on a relationship between early 
sleep problems and later development of ADHD could be 
replicated. As ICD-10 diagnosis for sleep disturbances are 
rarely used in the paediatric population, dispensed hypnotic 
medications for children was used as the exposure. We stud-
ied the association between dispensed hypnotics before age 
of 3 years, and diagnosed ADHD between 5 and 11 years of 
age, in all children born in Norway between 2004 and 2010. 
We further wanted to explore to what extent adjusting for 




In this cohort study, we linked information from the Norwe-
gian Prescription Database (NorPD), the Norwegian Patient 
Registry (NPR) and Statistics Norway, and used data span-
ning an 12 year time period (2004–2015). The unique person 
identifier held by all Norwegian inhabitants enabled us to 
link the different registries at an individual level.
All pharmacies have, since 2004, been obliged to reg-
ister electronically all dispensed prescribed drugs to indi-
viduals and send the information to the NorPD [26]. Each 
prescription is registered with drug information, including 
Anatomical Therapeutic Chemical (ATC) code [27, 28], date 
of dispensing and patient identifiers. The NorPD provided 
information on dispensed hypnotic drugs and stimulant 
medication.
The NPR is an administrative database containing activ-
ity data from all hospitals, private specialists and outpa-
tient clinics in Norway. Reporting to the NPR is mandatory 
and linked to the governmental reimbursement system for 
funding of health services. Every admission to a hospital 
or appointment with a specialist or outpatient clinic is reg-
istered with information such as date, diagnosis and patient 
data. All Norwegian residents are covered by the public 
health care system through a national insurance scheme. 
Health care is free of charge for children under 16 years. 
This implies that our data should capture all children diag-
nosed with ADHD in Norway. All diagnoses are reported 
according to the International Classification of Diseases, 
10th Revision, ICD-10 [29]. Individual data are available 
in the NPR since January 1st 2008, and we have used data 
from 2008 to 2015.
Statistics Norway provided the link between parents and 
children and information on the highest achieved educa-
tional level in 2014. Education is reported in nine categories 
according to the Norwegian Standard Classification of Edu-
cation [30]. Dates of death and emigration were available 
from the National Registry.
Population/Data Selection
Data from the NorPD, the NPR, Statistics Norway and the 
National Registry were linked using the encrypted per-
sonal identifier. All children born in Norway in the years 
2004–2010 were initially included in our study population, 
in total 429,158 children. 18,603 Children who died or emi-
grated before the age of 5 years were excluded. Our final 
selection consisted of 410,555 children.
Exposure
From the NorPD, we collected information about all pre-
scriptions for children under 3 years, for drugs known to 
be used in Norway as hypnotic drugs. In addition to the 
traditional anxiolytic and hypnotic drugs we also chose to 
include first generation antihistamines classified in ATC 
under respiratory system—antihistamines for systemic use 
(R06), but known to be sedating. There is a clinical tradition 
for using sedating antihistamines for sleep induction in small 
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children in Norway [19, 31]. These three medications were 
trimeprazine (R06AD01), prometazine (R06AD02), and 
dexchlorpheniramine (R06AB02). Hypnotics were defined 
as: anxiolytics (ATC Code N05BA: benzodiazepines), hyp-
notics and sedatives (N05C: benzodiazepine hypnotics, 
z-hypnotics, melatonin and chloral hydrate), trimeprazine 
(R06AD01), prometazine (R06AD02), and dexchlorphe-
niramine (R06AB02). All of these medications were only 
available by prescription at the time and not over-the-coun-
ter sale. Which means that all medication in this category 
should be captured by the NorPD [32].
As we only had access to birth month and birth year, 
we assigned a birth date in order to use the age of the chil-
dren in the analysis. We chose to set the birth date to the 
15th of the month for all children. This over- or under-esti-
mated the actual birthdate by no more than 16 days. We 
wanted to investigate use of medication in infancy and tod-
dler age, which is commonly considered to be from birth 
until 36 months of age. From the estimated birth date, a 
36 months “exposure window” was calculated and we col-
lected all dispensed prescriptions in this period. The medica-
tions were analysed separately and grouped together as the 
variable “all hypnotics”. A negligible number of toddlers 
received more than one hypnotic drugs during the exposure 
window. Also, investigating the effect of combined medica-
tion use was beyond the scope of this study. We stratified the 
exposure variable into those receiving no prescriptions, one 
prescription and two or more prescriptions. From before we 
know that around 70% of children who receive trimeprazine 
before 3 years of age only receive one prescription [25].
Outcome
For outcome, we identified all children who had at least two 
registered visits in specialised health care, resulting in an 
ICD-10 F90 (hyperkinetic disorder/ADHD) diagnosis from 
around school age of 5 years and onwards, either as main 
or secondary diagnosis in the NPR in the years 2008–2015. 
Time of outcome was for these children defined as time of 
the first diagnosis. Although the ICD-10-diagnosis F90 
hyperkinetic disorder is slightly narrower than the DSM-IV 
diagnosis ADHD it is considered equivalent in this study. 
The children were censored at death, at emigration or as of 
December 31st 2015, whichever occurred first.
Confounding Factors
For confounding factors, parental education was included 
to control for socioeconomic status of the family. Educa-
tion was stratified into two levels; “low” up to high school 
diploma and “high” including college and university edu-
cation. The level of education for one or both parents was 
registered for 407,608 children. All parents who had ever 
(2008–2015) been diagnosed with F90 hyperkinetic disorder 
registered in NPR or had ever (2004–2015) been dispensed 
a prescription for a stimulant medication (amphetamine 
N06BA01, dexamphetamine N06BA02, methylphenidate 
N06BA04, atomoxetine N06BA09, lisdexamphetamine 
N06BA12) in NorPD were considered to have ADHD. Treat-
ment with stimulant medication is regulated by the Nor-
wegian authorities and must be initiated by a specialist in 
psychiatry, neurology or paediatrics.
Statistical Analysis
Two types of statistical analyses were performed; χ2 testing 
and weighted Cox regression.
A bivariate analysis with χ2 test was performed for the 
association of children’s ADHD with use of (i) any hypnotic 
drug, (ii) dexchlorpheniramine (the most prevalent drug) and 
(iii) trimeprazine (the second most prevalent drug). We per-
formed the same analysis for (iv) parental ADHD and (v) 
parental educational level. Cramér’s bias corrected V was 
computed using the “cramerV” function in the R-package 
“rcompanion”.
Since follow-up time varied from 1 day to 7 years, Cox 
regression analyses were performed to estimate hazard rate 
ratios (HRs) associated with use of (i) any hypnotic drug, 
(ii) dexchlorpheniramine and (iii) trimeprazine. Time of out-
come was the time of the first of two ADHD diagnoses, and 
exposure was a 3-level categorical variable: 0 (reference), 
1, or ≥ 2 prescriptions before age 3. The Cox regression was 
adjusted with inclusion of parental ADHD as a two- level 
categorical variable; no parental ADHD (reference)/at least 
one parent with ADHD, and maternal and paternal educa-
tion as two two-level categorical variables; high school or 
less/university or college education (reference). We present 
Kaplan–Meier survival plots, and we tested the proportional 
hazards assumption using the “cox.zph” function in R. In 
some cases there was a significant deviance from proportion-
ality at a 5% level, and we therefore performed a weighted 
Cox regressions [33] using the “coxphw” function in R as 
well. Finally, we tested for interaction between gender and 
exposure.
The analyses were performed using IBM SPSS statistics 
version 22 and R version 3.5.2.
Results
Before the age of 3 years, 10.4% of the girls and 12.3% of 
the boys had been dispensed at least one prescription of a 
hypnotic drug. The two most prevalent drugs were dexchlor-
pheniramine (girls 6.7% and boys 7.9%) and trimeprazine 
(2.8% and 3.6%). The prevalence of the other hypnotics was 
as follows: diazepam (girls 1.5%, boys 1.7%), melatonin 
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(0.1% and 0.2%), nitrazepam (0.05% and 0.06%), mida-
zolam (0.02% and 0.03%), clobazam (0.02% and 0.02%), 
oxazepam, promethazine, zopiclone, zolpidem (all < 0.01%) 
(data not shown in table).
Use of hypnotic drugs at age 0–3 was more prevalent 
among children who later received an ADHD diagnosis than 
among other children (girls 18.9% vs 10.3%, boys 20.1% vs 
12.2%, Table 1). For trimeprazine the corresponding num-
bers were 7.6% vs 2.8% in girls and 7.4% vs 3.5% in boys 
(Table 1).
Of the children who developed ADHD, 17.4% had at 
least one parent with ADHD whereas only 2.6% of the chil-
dren without ADHD had at least one parent with ADHD 
(Table 2). Among the children with and without ADHD 
the percentage of maternal lower education was 66.3% and 
46.8%, respectively (Table 2).
The proportional hazards assumption of the Cox regres-
sion was not fulfilled for all regressions. For girls, the HR 
associated with ≥ 2 prescriptions tended to decrease over 
time both for hypnotics and for trimeprazine (p-values for 
proportionality were 0.001 and 0.0005, respectively). This 
can also be seen from the Kaplan–Meier survival plots 
(Figs. 1, 2). In particular for trimeprazine, the survival 
curves for exposed with ≥ 2 prescriptions start to drop before 
the curves for the unexposed. The p-value for proportional-
ity was < 0.05 for 4 of the 12 adjusted HRs in Table 3. We 
therefore present the average the HRs from the weighted Cox 
regression (wHR) in Table 3 for all HRs.
With standard Cox regression we also found significant 
gender interactions, with a higher HR of ADHD associ-
ated with ≥ 2 prescriptions both for all hypnotics and for 
trimeprazine in girls than in boys (p-values for interaction 
were 0.005 and 0.021 for all hypnotics and for trimeprazine, 
respectively). The weighted Cox regression did not reveal 
any statistically significant interactions, but we have chosen 
to still present the results separately for boys and girls.
The unadjusted wHR for receiving a later diagnosis of 
ADHD when dispensed one prescription for any hypnotics 
from birth to 3 years of age, as compared to no prescrip-
tions, was 1.23 (95% CI 1.02–1.49) for girls and 1.32 for 
boys (1.18–1.47) (Table 3). The wHR when being dispensed 
at least two prescriptions as compared to no prescriptions 
was 2.30 (1.63–3.23) for girls and 1.75 (1.48–2.07) for boys 
(Table 3). Being dispensed dexchlorpheniramine was less 
related to a future ADHD diagnosis. For those who filled one 
prescriptions for trimeprazine the wHR was 2.02 (1.52–2.69) 
for girls and 1.62 (1.36–1.93) for boys and for two or more 
prescriptions the figures were 3.71 (1.83–7.52) and 2.78 
(2.04–3.80) for girls and boys respectively. Parent’s educa-
tional level and especially a parental ADHD diagnosis was 
highly related to the child’s later ADHD diagnosis (Table 2). 
After adjusting for the important factors (parent’s ADHD 
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more prescriptions for any hypnotic drug had a HR for being 
diagnosed with ADHD of 1.99 (1.40–2.83) for girls and 1.58 
(1.34–1.87) for boys. The adjusted HR of ADHD after being 
dispensed trimeprazine once was 1.76 (1.32–2.34) for girls 
and 1.50 (1.25–1.78) for boys. After being dispensed trime-
prazine twice or more, the HR was 2.81 (1.34–5.88) for girls 
and 2.33 (1.70–3.20) for boys, respectively.
Discussion
Being dispensed any hypnotic drug twice or more before 
the age of 3 years, doubled the risk of a later ADHD diag-
nosis for girls and increased the risk by 60% for boys even 
after controlling for known risk factors such as parental 
ADHD and parental educational level. The risk after being 
dispensed the sedative antihistamine trimeprazine was even 
higher. The increased risk of ADHD diagnosis when receiv-
ing two or more prescriptions as opposed to one prescription 
indicates a dose–response relationship where more severe 
sleep problems further increased the risk of later receiving 
a diagnosis of ADHD.
From birth to the age of 3 years, a little over 10% of both 
girls and boys received prescriptions for sleep inducing 
drugs. The most frequent drugs, dexchlorpheniramine and 
trimeprazine, are both first generation antihistamines, not 
traditional hypnotics. But unlike newer antihistamines these 
substances cross the blood–brain barrier and have sedating 
effects. In Norway there is a long-standing clinical tradi-
tion for prescribing the sedative antihistamine trimeprazine 
on a large scale for infants and toddlers as a sleep inducer 
[24]. Dexchlorpheniramine and trimeprazine have similar 
effects, but the reimbursements (unpublished data). Among 
children 0–3 years of age more than 40% of prescriptions for 
dexchlorpheniramine were reimbursed for allergy whereas 
only 2% of alimemazine prescriptions were reimbursed for 
allergy/pruritus. As sleep problems is the only other indica-
tion for prescribing trimeprazine this could mean that trime-
prazine to a large extent is used to treat sleep disturbances. 
Recommending antihistamines for sleep induction is well 
known in US settings [34] and studies from Europe report 
frequent use of systemic antihistamines for small children 
[35, 36]. Melatonin has over the last years emerged as the 
first choice hypnotic for paediatric insomnia [37] although 
long term safety studies on children are still missing [38]. 
Melatonin is not predominantly prescribed for the youngest 
age group in Norway [18, 23], and is mainly prescribed for 
children with psychiatric or neurological conditions [37]. In 
the observational time of the study melatonin was not avail-
able for sale in Norway without prescription. In Norway, it 
Table 2  Bivariate analysis 
showing parents’ ADHD and 
parents’ education by whether 
or not the child was diagnosed 
with ADHD after 5 years of age
a Missing values were replaced by information from the other parent. For 2947 children none of the parents 
had registered education information
b Information not available (NA) for any parent
c Test observator and [degrees of freedom (df)] and p-value from χ2 test
d Cramér’s bias corrected V
ADHD, child N total χ2 (df)c p-valuec Vd
No Yes
Mother ADHD
 No 398,598 98.6% 5748 88.8% 404,346 4101 (1)  < 0.001 0.010
 Yes 5487 1.4% 722 11.2% 6209
Father ADHD
 No 398,653 98.7% 5985 92.5% 404,638 1692 (1)  < 0.001 0.006
 Yes 5432 1.3% 485 7.5% 5917
One or both parents 
have ADHD
 No 393,680 97.4% 5345 82.6% 399,025 5114 (1)  < 0.001 0.011
 Yes 10,405 2.6% 1125 17.4% 11,530
Mother’s  educationa
 NAb 2931 0.7% 16 0.3% 2947 968 (2)  < 0.001 0.005
 Low 189,267 46.8% 4287 66.3% 193,554
 High 211,887 52.4% 2167 33.5% 214,054
Father’s  educationa
 NAb 2931 0.7% 16 0.3% 2947 925 (2)  < 0.001 0.005
 Low 246,381 61.0% 5145 79.5% 251,526
 High 154,773 38.3% 1309 20.2% 156,082
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is thus reasonable to use prescriptions for trimeprazine as a 
proxy for challenges with sleep in infants and toddlers.
Girls who received sleep medication were more likely 
to be diagnosed with ADHD than boys who received sleep 
medication. Several studies find that toddler boys sleep less 
that girls [39, 40]. Perhaps is the threshold for sleep medi-
cation in boys lower than that for girls, and the girls who 
received a prescription for a sleep medication had more seri-
ous sleep problems than boys.
The association between dispensed hypnotic drugs and 
later ADHD could have several explanations. Although we 
believe that hypnotic use serves as a proxy for an under-
lying sleep problem, it could be argued that a direct drug 
effect on the brain development explains the association. 
The aetiology of ADHD is multifaceted, but even if drugs 
like trimeprazine and dexchlorpheniramine influence a num-
ber of receptors in the brain [41], such a direct effect on 
the brain facilitating ADHD seems biologically unlikely; 
mostly because the drugs are used for a short period of time 
[25]. Also, the differences in risk following the quite similar 
drugs trimeprazine and dexchlorpheniramine [42–44] used 
for different indications, trimeprazine used as hypnotic and 
dexchlorpheniramine for allergy, suggest that the increase 
in risk of ADHD is not a drug effect but could, rather, be 
related to the reasons for the drug use.
Problems with sleep are frequent in both adults and chil-
dren with ADHD [45, 46]. A meta-analysis has shown that 
infant sleep problems predict difficult temperament or prob-
lem behaviour later in life [3], but the analysis was based on 
small and heterogeneous studies mainly based on maternal 
report of regulation problems. Most studies used the par-
ent report Child Behaviour Checklist as measurement of 
behavioural problems. Several studies have shown that sleep 
problems are related to the later development of ADHD 
symptoms [3, 8–10]. Studies using diagnostic ADHD show 
both an increase in ADHD related to early severe sleeping 
problems [11, 12], while other fail to replicate this [13, 14]. 
The present study found an association between dispensed 
hypnotics from birth to age 3 and a diagnosis of ADHD 
in school age set by specialists in Child and Adolescent 
Psychiatry. Using dispensed hypnotic drugs as a proxy for 
severe sleep problems, our cohort study supports those who 
Fig. 1  Kaplan–Meier sur-
vival plots for hypnotics. The 
unexposed, exposed 1 and 
exposed 2+ group had 0, 1, 
and 2+ prescriptions of any 
hypnotic, respectively at age 
0–3 years. Follow-up started at 
age 5. Numbers in the at risk 
table below the figure show the 
population at risk at baseline 
and after 1, 2,…,6 years
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have found a relationship between early sleeping problems 
and later diagnosis of ADHD in a population of more than 
400,000 children followed from the age of 5 years up to 
11 years, without loss to follow up [11, 47].
There could be several explanations for the association 
between sleep problems and later ADHD. Sleep problems 
could be an early symptom of ADHD preceding diagno-
sis. Other studies have shown modest to strong stability of 
ADHD-like symptoms from 18 months and throughout pre-
school years [48]. Alternatively, early sleep problems and 
ADHD could have shared aetiology. Dysregulation of the 
hypothalamic–pituitary–adrenocortical axis or circadian 
rhythm disturbances could affect both sleep regulation and 
attention or activity levels [49, 50]. There is also evidence 
pointing to a common factor of abnormalities in the dopa-
mine system [51]. Lastly, sleep problems could be caus-
ally linked to ADHD. Several studies describe how limited 
amounts of sleep can cause impairment in neurobehavioral 
functioning [52, 53]. Sleep deprivation might influence the 
development of ADHD, either directly via neural loss or 
indirectly in a cascade where individuals who experience 
loss of sleep are more susceptible to negative stimuli and 
show more negative affect [52–54].
The association between dispensed sleep medication and 
later ADHD diagnosis could be biased by family and social 
background. Family adversities have been shown to be a 
more important explanation for the development of hyper-
kinetic traits than infant regulation problems [55]. The asso-
ciation between dispensed sleep medication and ADHD in 
childhood is also confounded by parental ADHD. Parents 
with ADHD could, through their own sleep problems, have 
low tolerance for small children’s variable sleep patterns 
and be more likely to seek medical advice and have sleep 
medications prescribed for their children. A previous study 
showed that hypnotics dispensed to parents doubled the 
chance of a prescription for trimeprazine being filled for a 
toddler [25]. However, in our study, use of hypnotic drugs 
was associated with an increased risk of ADHD indepen-
dently of parental ADHD and parental education.
The ADHD prevalence rates in the present study were low 
compared to what is found internationally [56], but similar to 
other studies from Scandinavia [57, 58]. The use of ICD-10 
Fig. 2  Kaplan–Meier survival 
plots for trimeprazine. The 
unexposed, exposed 1 and 
exposed 2+ group had 0, 1, and 
2+ prescriptions of trime-
prazine, respectively at age 
0–3 years. Follow-up started at 
age 5. Numbers in the at risk 
table below the figure shows at 
risk population at baseline and 
after 1, 2,…,6 years
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criteria for diagnosis could explain some of this discrepancy 
[59]. In addition, the prevalence of ADHD increases steeply 
during childhood [58, 60] and we may have underestimated 
the prevalence of ADHD due to a limited follow-up period. 
It is, however, unlikely that the timing of diagnosis is related 
to the use of hypnotic drugs, and thus our low prevalence 
rates will not bias the calculated risk.
We do unfortunately not have information on sleep diag-
nosis in the age 0–3 years as the Norwegian prescription 
database does not contain diagnosis unless medications are 
reimbursed and hypnotics are not reimbursed for insomnia 
or sleep disturbances in general [32]. Sleep diagnosis were 
also not available from the Norwegian Patient Registry as 
there seems to be a clinical tradition for not using the ICD-
10 G47 Sleep Disorders diagnosis for children. Using sleep 
medications as a proxy for sleep problems is an effort to col-
lect large objective data for a complex condition for which 
data on diagnosis are not available.
ICD-10 diagnosis of hyperkinetic disorder is narrower 
than the DSM IV diagnosis of ADHD, as the inattentive type 
ADHD is not formally included in ICD-10. This subgroup 
was thus not included in our study. This could introduce an 
unknown bias, but overall, the exposed group in this study 
probably includes children with more severe sleep problems 
and possibly more severe forms of ADHD, possibly leading 
to a slight overestimation of the association between sleep 
problems and ADHD.
The proportional hazards assumption of the Cox regres-
sion was not fulfilled for all of the regressions, and we there-
fore present average hazard ratios from weighted estimation 
in Cox regression. These were quite close to the estimates 
from standard Cox regression although the confidence inter-
vals were roughly twice as large.
Summary
This study investigates a complete cohort of 410,555 chil-
dren born in Norway in the years 2004–2010. We have cap-
tured dispensed hypnotic drugs from birth to 3 years of age 
and all diagnoses for ADHD from 5 years of age and up to 
the age of 11 years set by specialists in Child and Adolescent 
Psychiatry. It has previously been shown that infant regula-
tion problems, including sleep problems, is associated with 
ADHD diagnosis. We replicate this finding in large cohort, 
where continuous data collection ensures no recall bias and 
no loss to follow up. We find that the use of hypnotic drugs 
before 3 years of age signifying substantial sleeping prob-
lems increases the risk of a later ADHD diagnosis. This was 
especially true for the antihistaminergic drug, trimeprazine.
Table 3  The hazard ratio of 
ADHD at school age after using 
hypnotic drug trimeprazine 
between the ages 0 and 3 years 
for children born between 2004 
and 2011
a The full model is adjusted for paternal and maternal education (high/low) and for parental ADHD (no/at 
least one parents with ADHD)
b With a Bonferroni correction for multiple testing a test would have to have p < 0.0042 to be significant
Unadjusted Adjusteda
HR 95% CI p-valueb HR 95% CI p-valueb
Girls
 No hypnotics (reference) 1.00 1.00
 All hypnotics one prescription 1.23 1.02–1.49 0.026 1.18 0.98–1.42 0.080
 All hypnotics twice or more 2.30 1.63–3.23  < 0.001 1.99 1.40–2.83  < 0.001
 No dexchlorpheniramine (reference) 1.00 1.00
 Dexchlorpheniramine one prescription 1.31 0.94–1.82 0.113 1.27 0.91–1.78 0.161
 Dexchlorpheniramine twice or more 1.23 0.85–1.80 0.270 1.11 0.76–1.62 0.587
 No trimeprazine (reference) 1.00 1.00
 Trimeprazine one prescription (ref 0) 2.02 1.52–2.69  < 0.001 1.76 1.32–2.34  < 0.001
 Trimeprazine twice or more 3.71 1.83–7.52  < 0.001 2.81 1.34–5.88 0.006
Boys
 No hypnotics (reference) 1.00 1.00
 All hypnotics one prescription (ref 0) 1.32 1.18–1.47  < 0.001 1.28 1.15–1.42  < 0.001
 All hypnotics twice or more 1.75 1.48–2.07  < 0.001 1.58 1.34–1.87  < 0.001
 No dexchlorpheniramine (reference) 1.00 1.00
 Dexchlorpheniramine one prescription (ref 0) 1.27 1.09–1.48 0.002 1.24 1.07–1.44 0.005
 Dexchlorpheniramine twice or more 1.27 1.04–1.55 0.018 1.18 0.97–1.44 0.100
 No trimeprazine (reference) 1.00 1.00
 Trimeprazine one prescription (ref 0) 1.62 1.36–1.93  < 0.001 1.50 1.25–1.78  < 0.001
 Trimeprazine twice or more 2.78 2.04–3.80  < 0.001 2.33 1.70–3.20  < 0.001
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